HCV direct-acting antiviral agents: the best interferon-free combinations

Authors

  • Raymond Schinazi,

    Corresponding author
    1. Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, USA
    • Correspondence

      Raymond F. Schinazi, PhD, DSc, Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, Georgia 30033, USA

      Tel: +1 404 727 1414

      Fax: +1 404 727 1330

      e-mail: rschina@emory.edu

      (or)

      Tarik Asselah, MD, PhD, Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, 100 Bd du Général Leclerc, Clichy 92110, France

      Tel: +33(0) 140875579

      Fax: +33(0) 147309440

      e-mail: tarik.asselah@bjn.aphp.fr

    Search for more papers by this author
  • Philippe Halfon,

    1. Internal Medicine and Infectious Diseases Department, Hôpital Europeen and Laboratoire Alphabio Marseille, Marseille, France
    Search for more papers by this author
  • Patrick Marcellin,

    1. Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Search for more papers by this author
  • Tarik Asselah

    Corresponding author
    1. Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    • Correspondence

      Raymond F. Schinazi, PhD, DSc, Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, Georgia 30033, USA

      Tel: +1 404 727 1414

      Fax: +1 404 727 1330

      e-mail: rschina@emory.edu

      (or)

      Tarik Asselah, MD, PhD, Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, 100 Bd du Général Leclerc, Clichy 92110, France

      Tel: +33(0) 140875579

      Fax: +33(0) 147309440

      e-mail: tarik.asselah@bjn.aphp.fr

    Search for more papers by this author

Abstract

For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan-genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross-resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.

Ancillary